Propanc Biopharma, Inc. - Common Stock (PPCB)

MELBOURNE, Australia, Oct. 30, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases including recurrent and metastatic cancer, today announced that key analytical development activities are underway, including immunogenicity assay feasibility, pharmacokinetic method optimization and stability testing, supporting preparations for the planned Phase 1b, First-In-Human study of the Company’s lead clinical candidate, PPC-001, in up to 50 advanced cancer patients with solid tumors.

Human Research Ethics Submission Deadline Nov ‘26 with Site Initiation Activities Followed by First Patient Screening Planned for Feb ‘27

Peer-Reviewed Scientific Reports Data & Academic Collaboration Show Potent Anti-Tumor Activity, EMT Reversal, & Sequential Chemo-Sensitization; Phase 1b First-In-Human Study Planned for Q1 2027

Clears Pathway for Execution of Future R&D Milestone Events such as the Phase 1b, FIH Study for PRP in up to 50 Advanced Cancer Patients with Solid Tumors, First Quarter, 2027

Clears Pathway for Execution of Future R&D Milestone Events such as the Phase 1b, FIH Study for PRP in up to 50 Advanced Cancer Patients with Solid Tumors, First Quarter, 2027

New Preclinical Findings Identify Potential Strategy to Remodel Resistant Tumor State & Restore Therapeutic Vulnerability

Scientific Reports Paper Shows Synergistic Trypsinogen/Chymotrypsinogen A Combination (1:6) Inhibits Angiogenesis, Migration, Invasion and EMT While Delivering Significant Tumor Reduction in Orthotopic Models and Encouraging Survival Signals in Advanced Patients

Preclinical package also shows more than 2.5-fold survival extension in advanced PDAC models; Company contrasts a non-RAS, differentiation-based mechanism with the clinical benchmark set by RASONQUE (daraxonrasib)

Plans To Commence World-First Phase 1b First-In-Human (FIH) Study of PRP Q1, 2027

New Preclinical PDAC Package for PRP Shows >90% Tumor-Growth Inhibition & >2.5-Fold Survival Benefit; Company Contrasts Mechanism, Breadth, & Development Role Against Erasca’s Phase 1 ERAS-0015 Dataset

New Preclinical PDAC Data for PRP Show >90% Tumor-Growth Inhibition & >2.5-Fold Survival Benefit; Company Highlights How Reversing Epithelial-Mesenchymal Transition May Deepen & Extend Responses to RAS(ON) & Pan-RAS Therapies

Open-label, two-part dose-escalation and dose-expansion study planned in up to 50 patients with advanced solid tumors across Australia

Differentiated Profile versus RAS-Targeted Approaches Including Revolution Medicines’ Daraxonrasib

Avance Clinical to Lead Preparatory Activities for Multi-Center Investigation Across Australia

Contrasting Science with Revolution Medicines and Erasca

Accelerates Phase 1b First-in-Human Trial Timeline

Purchasing $500,000 within First 30 days Since Program Commencement

A Promising Strategy for Improving Production for Applications in Biotechnology Research

Sets out Shared Intent to Support Delivery of Propanc’s First-In-Human Clinical Trial for PRP

The Company to Purchase First Tranche of Up to $500,000 over the next 30-day period

Pre-production, Engineering Run and GMP Manufacture of PRP in 2026

Management Believes the Company is Entering a Transformative Stage with a Novel, First-In-Class Cancer Therapy for Treatment & Prevention of Metastatic Cancer from Solid Tumors

Dr. Juan Carlos Izpisúa Provides the UGR With the Keys to Science Against Ageing

Plans to File CTA for Ph. 1b, FIH Study, 30 – 40 Advanced Cancer Patients in ‘26

Provides End-To-End Services for Preclinical & Clinical Projects with Extensive Experience in Decoding Biologics Production